PLA2G10 and neoplasm: In a syngeneic tumor graft model, overexpression of sPLA2-X in immunogenic tumor cells prevents the infiltration of CD8+ T and natural killer cells, thereby conferring resistance to anti-PD-1 immunotherapy.